124 related articles for article (PubMed ID: 28487611)
1. Performance of 18-fluoro-2-deoxyglucose positron emission tomography for esophageal cancer screening.
Sekiguchi M; Terauchi T; Kakugawa Y; Shimada N; Saito Y; Matsuda T
World J Gastroenterol; 2017 Apr; 23(15):2743-2749. PubMed ID: 28487611
[TBL] [Abstract][Full Text] [Related]
2. Clinical relevance of fluorodeoxyglucose positron emission tomography/computed tomography and magnifying endoscopy with narrow band imaging in decision-making regarding the treatment strategy for esophageal squamous cell carcinoma.
Toriyama K; Tajika M; Tanaka T; Ishihara M; Hirayama Y; Onishi S; Mizuno N; Kuwahara T; Okuno N; Matsumoto S; Sasaki E; Abe T; Yatabe Y; Hara K; Matsuo K; Tamaki T; Niwa Y
World J Gastroenterol; 2019 Dec; 25(46):6767-6780. PubMed ID: 31857778
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the diagnostic value of 3-deoxy-3-18F-fluorothymidine and 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the assessment of regional lymph node in thoracic esophageal squamous cell carcinoma: a pilot study.
Han D; Yu J; Zhong X; Fu Z; Mu D; Zhang B; Xu G; Yang W; Zhao S
Dis Esophagus; 2012 Jul; 25(5):416-26. PubMed ID: 21951837
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity of 2-[
Sekiguchi M; Kakugawa Y; Terauchi T; Matsumoto M; Saito H; Muramatsu Y; Saito Y; Matsuda T
J Gastroenterol; 2016 Dec; 51(12):1122-1132. PubMed ID: 27021493
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of esophageal cancer during the pretreatment of hypopharyngeal cancer patients: routinely performed esophagogastroduodenoscopy and FDG-PET/CT findings.
Nakaminato S; Toriihara A; Makino T; Kawano T; Kishimoto S; Shibuya H
Acta Oncol; 2012 May; 51(5):645-52. PubMed ID: 22229748
[TBL] [Abstract][Full Text] [Related]
6. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma.
Swisher SG; Erasmus J; Maish M; Correa AM; Macapinlac H; Ajani JA; Cox JD; Komaki RR; Hong D; Lee HK; Putnam JB; Rice DC; Smythe WR; Thai L; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
Cancer; 2004 Oct; 101(8):1776-85. PubMed ID: 15386332
[TBL] [Abstract][Full Text] [Related]
7. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma.
Flamen P; Lerut A; Van Cutsem E; De Wever W; Peeters M; Stroobants S; Dupont P; Bormans G; Hiele M; De Leyn P; Van Raemdonck D; Coosemans W; Ectors N; Haustermans K; Mortelmans L
J Clin Oncol; 2000 Sep; 18(18):3202-10. PubMed ID: 10986052
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma.
Hyun SH; Choi JY; Shim YM; Kim K; Lee SJ; Cho YS; Lee JY; Lee KH; Kim BT
Ann Surg Oncol; 2010 Jan; 17(1):115-22. PubMed ID: 19826877
[TBL] [Abstract][Full Text] [Related]
9. Fluorine-18 fluorodeoxyglucose positron emission tomography in the preoperative staging of thoracic oesophageal and gastro-oesophageal junction cancer: a prospective study.
Katsoulis IE; Wong WL; Mattheou AK; Damani N; Chambers J; Livingstone JI
Int J Surg; 2007 Dec; 5(6):399-403. PubMed ID: 17631431
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of FDG-PET in screening of synchronous cancer of other organs in patients with esophageal cancer.
Miyazaki T; Sohda M; Higuchi T; Tanaka N; Suzuki S; Sakai M; Yokobori T; Nakajima M; Fukuchi M; Tsushima Y; Kato H; Kuwano H
Anticancer Res; 2014 Jan; 34(1):283-7. PubMed ID: 24403475
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer.
Levine EA; Farmer MR; Clark P; Mishra G; Ho C; Geisinger KR; Melin SA; Lovato J; Oaks T; Blackstock AW
Ann Surg; 2006 Apr; 243(4):472-8. PubMed ID: 16552197
[TBL] [Abstract][Full Text] [Related]
12. Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography.
Flanagan FL; Dehdashti F; Siegel BA; Trask DD; Sundaresan SR; Patterson GA; Cooper JD
AJR Am J Roentgenol; 1997 Feb; 168(2):417-24. PubMed ID: 9016218
[TBL] [Abstract][Full Text] [Related]
13. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
14. Prediction of survival and evaluation of diagnostic accuracy whole body 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in the detection carcinoma of unknown primary origin.
Tamam MO; Mulazimoglu M; Guveli TK; Tamam C; Eker O; Ozpacaci T
Eur Rev Med Pharmacol Sci; 2012 Dec; 16(15):2120-30. PubMed ID: 23280029
[TBL] [Abstract][Full Text] [Related]
15. Performance profile of FDG-PET and PET/CT for cancer screening on the basis of a Japanese Nationwide Survey.
Minamimoto R; Senda M; Uno K; Jinnouchi S; Iinuma T; Ito K; Okuyama C; Oguchi K; Kawamoto M; Suzuki Y; Tsukamoto E; Terauchi T; Nakashima R; Nishio M; Nishizawa S; Fukuda H; Yoshida T; Inoue T
Ann Nucl Med; 2007 Nov; 21(9):481-98. PubMed ID: 18030580
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of whole-body cancer screening using 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography: a preliminary report.
Terauchi T; Murano T; Daisaki H; Kanou D; Shoda H; Kakinuma R; Hamashima C; Moriyama N; Kakizoe T
Ann Nucl Med; 2008 Jun; 22(5):379-85. PubMed ID: 18600415
[TBL] [Abstract][Full Text] [Related]
17. Significance of 18F-Fluorodeoxyglucose Uptake at the Gastroesophageal Junction: Comparison of PET to Esophagogastroduodenoscopy.
Stagg J; Farukhi I; Lazaga F; Thompson C; Bradshaw L; Kaif M; Gould-Simon A; Schmidt R
Dig Dis Sci; 2015 May; 60(5):1335-42. PubMed ID: 25502332
[TBL] [Abstract][Full Text] [Related]
18. Limitations of FDG-PET and FDG-PET with computed tomography for detecting synchronous cancer in pharyngeal cancer.
Suzuki H; Hasegawa Y; Terada A; Ogawa T; Hyodo I; Suzuki M; Nakashima T; Tamaki T; Nishio M
Arch Otolaryngol Head Neck Surg; 2008 Nov; 134(11):1191-5. PubMed ID: 19015450
[TBL] [Abstract][Full Text] [Related]
19. Incremental value of 18F-FDG PET/CT in therapeutic decision-making of potentially curable esophageal adenocarcinoma.
Purandare NC; Pramesh CS; Karimundackal G; Jiwnani S; Agrawal A; Shah S; Kulkarni M; Laskar SG; Rangarajan V
Nucl Med Commun; 2014 Aug; 35(8):864-9. PubMed ID: 24751701
[TBL] [Abstract][Full Text] [Related]
20. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role?
Cuellar SL; Carter BW; Macapinlac HA; Ajani JA; Komaki R; Welsh JW; Lee JH; Swisher SG; Correa AM; Erasmus JJ; Hofstetter WL
J Thorac Oncol; 2014 Aug; 9(8):1202-6. PubMed ID: 25157774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
